Dude, don't mislead people like that...
...and certainly don't circle your calendar. That date has little to no expected meaning for Genta. Sure' they're presenting at the largest Biotech investors conference on the planet, but it really doesn't have much to do with Genasense approval. If anything, there might be positive news about financing, but little more (maybe an update on the Agenda Phase III trial).
What people should be focused on is the Agenda Phase III trial and the awesome results that it is producing. What we also need to think about is why the FDA has turned down such a great and needed product like Genasense. It has proven results and efficacy in double blind, placebo based studies conducted around the world.
This is coming from someone who has been in this stock since .0022. I've done my DD and have to laugh at some of the posts here. Genta will realize it's market value without all the hype. They have proven, groundbreaking drugs in their pipeline and one on the market.
If they by some chance don't make it on their own, one of the larger Pharma's is going to scoop them up as the acquisition dominoes continue to fall (first one kicked over by Pfizer).
Bottom line? Don't expect huge news about FDA approval at the investors conference on the 9th, but do expect some great news from the FDA some time this quarter or 2nd quarter 2009.
The Agenda Phase III trial is expected to be fully enrolled shortly and I expect the results will continue to roll in.
If you're in now for under a penny, my advice would be to say your blessings and hang on to those shares tight. The potential here for an anticancer drug like Genasense simply can't be overstated.
Best of luck to everyone.
